


IHCP *bulletin*

INDIANA HEALTH COVERAGE PROGRAMS BT201708 JANUARY 26, 2017

IHCP revises PDL status for hydroxyprogesterone caproate


The Indiana Health Coverage Programs (IHCP) announces a revision to the Preferred Drug List (PDL) status for hydroxyprogesterone caproate. *IHCP Bulletin BT201682*, published November 29, 2016, listed hydroxyprogesterone caproate with a “Preferred” status on the PDL beginning January 1, 2017. Effective March 1, 2017, hydroxyprogesterone caproate will change to a “Nonpreferred” status. This change applies to fee-for-service (FFS) pharmacy benefits for dates of service (DOS) on or after March 1, 2017. The PDL can be accessed under the [Pharmacy Services](#) link at indianamedicaid.com.

Please direct FFS prior authorization (PA) requests and questions about the FFS PDL or this bulletin to the OptumRx Clinical and Technical Help Desk by calling toll-free 1-855-577-6317. Questions regarding pharmacy benefits for members in the Healthy Indiana Plan (HIP), Hoosier Healthwise, and Hoosier Care Connect should be referred to the managed care entity with which the member is enrolled.



SIGN UP FOR IHCP EMAIL NOTIFICATIONS

To receive email notices of IHCP publications, subscribe by clicking the blue subscription envelope here or on the pages of indianamedicaid.com.



COPIES OF THIS PUBLICATION

If you need additional copies of this publication, please [download them](#) from indianamedicaid.com.

TO PRINT

A [printer-friendly version](#) of this publication, in black and white and without graphics, is available for your convenience.